WATERTOWN, Mass., April  16, 2024  (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced it will be holding a virtual corporate R&D event on April 24th, 2024 from 4:15 p.m. to 5:30 p.m. ET. The agenda will feature presentations by Acrivon's leadership team followed by an interactive Q&A session.

"We are very excited to share key updates across our AP3-driven pipeline and to highlight the power of employing our precision phosphoproteomics-based approach both for drug discovery and development," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. "We also look forward to sharing initial ACR-368 clinical data based on prospective patient responder identification with our ACR-368 OncoSignature assay, as well as preclinical updates on ACR-2316, our internally discovered, potent, single agent active WEE1/PKMYT1 inhibitor, and other pipeline progress. We will also provide a demonstration of our proprietary, machine learning-enabled AP3 Interactome, an interactive tool we leverage to uncover actionable drug-induced pathway effects across all our studies."

A live webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company's website. The webcast will be available for at least 30 days following the event.